XCancer

UPCC 04219 Phase 2 Study of Capecitabine-Temozolomide(CapTem) With Yttrium-90 Radioembolization in the Treatment of Patients With Unresectable Metastatic Grade 2 Neuroendocrine Tumors

Description:

This is a Phase 2 evaluation of hepatic-progression free survival among patients with Grade 2 liver-dominant NET metastases undergoing combination therapy with CapTem and Y90 radioembolization.The hypothesis is to confirm safety and to assess if disease control is improved relative to expectation from either therapy alone.

Sponsor:

Abramson Cancer Center of the University of Pennsylvania

Phase:

Phase 2

Contacts:

Michael Soulen, MD

michael.soulen@pennmedicine.upenn.edu

855-216-0098

Kathleen Thomas

kathleen.thomas@pennmedicine.upenn.edu

215-746-0352

Government Study Link:

NCT04339036 - Click here to see study on

ClinicalTrials.gov

Isotope(s):
Target(s):